(Q36328410)

13 August 2017

1 reference

title

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? (English)

1 reference

stem cell transplantation

13 August 2017

1 reference

1 reference

1 reference

John Goldman

1

1 reference

PubMed ID

16321820

13 August 2017

Myrtle Gordon

series ordinal

2

1 reference

PubMed ID

16321820

13 August 2017

language of work or name

1 reference

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

47

1 reference

13 August 2017

1

1 reference

13 August 2017

1-7

1 reference

Stem cells, cancer, and cancer stem cells

13 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

CD34- hematopoietic stem cells: current concepts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Chronic myeloid leukaemia: stem cell derived but progenitor cell driven

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Molecules and mechanisms of the graft-versus-leukaemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Dynamics of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Drug resistance in cancer: principles of emergence and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500407996

10.1080/10428190500407996

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16321820